A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naive prostate cancer (mHNPC): ZZFIRST.

被引：1
|
作者：
Mateo, Joaquin
Borque, Angel
Castellano, Daniel E.
Castro, Elena
Climent Duran, Miguel Angel A.
Font, Albert
Lorente, David
Mellado, Begona
Rodriguez-Vida, Alejo
Cuadras, Merce
Planas, Jacques
Casanova Salas, Irene
Cordoba, Sarai
Gonzalez, Lucila
Martinez de Falcon, Marta
Fernandez, Melissa
Sampayo-Cordero, Miguel
Malfettone, Andrea
Perez-Lopez, Raquel
Carles, Joan
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Hosp Univ Miguel Servet, Zaragoza, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Virgen Victoria & Reg Malaga, Inst Invest Biomed Malaga, Malaga, Spain
[5] Inst Valenciano Oncol IVO, Valencia, Spain
[6] Inst Catala Oncol, Badalona, Spain
[7] Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain
[8] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[9] Hosp Mar, Res Inst, Med Oncol Dept, Barcelona, Spain
[10] Vall dHebron Inst Oncol, Barcelona, Spain
[11] Vall dHebron Univ Hosp, Barcelona, Spain
[12] Vall dHebron Univ Hosp, Urol Dept, Barcelona, Spain
[13] Med Sci Innovat Res MEDSIR, Barcelona, Spain
[14] Vall dHebron Inst Oncol VHIO, Radiom Grp, Barcelona, Spain
[15] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS209
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a randomized prospective multicenter clinical trial
    Waltregny, D
    Boca, P
    Nicolas, H
    Youssef, E
    Jeukenne, M
    Bouffioux, C
    Coppens, L
    Andrianne, R
    Bonnet, P
    De Leval, J
    JOURNAL OF UROLOGY, 2002, 167 (04): : 175 - 175
  • [22] First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
    Fizazi, Karim
    Azad, Arun A.
    Matsubara, Nobuaki
    Carles, Joan
    Fay, Andre P.
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Voog, Eric
    Jones, Robert J.
    Shore, Neal D.
    Dunshee, Curtis
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Ye, Dingwei
    Lin, Xun
    Healy, Cynthia G.
    Di Santo, Nicola
    Laird, A. Douglas
    Zohren, Fabian
    Agarwal, Neeraj
    NATURE MEDICINE, 2024, 30 (01) : 257 - +
  • [23] First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
    Karim Fizazi
    Arun A. Azad
    Nobuaki Matsubara
    Joan Carles
    Andre P. Fay
    Ugo De Giorgi
    Jae Young Joung
    Peter C. C. Fong
    Eric Voog
    Robert J. Jones
    Neal D. Shore
    Curtis Dunshee
    Stefanie Zschäbitz
    Jan Oldenburg
    Dingwei Ye
    Xun Lin
    Cynthia G. Healy
    Nicola Di Santo
    A. Douglas Laird
    Fabian Zohren
    Neeraj Agarwal
    Nature Medicine, 2024, 30 : 257 - 264
  • [24] TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
    Agarwal, Neeraj
    Shore, Neal D.
    Dunshee, Curtis
    Ivan Karsh, Lawrence
    Azad, Arun
    Fay, Andre P.
    Carles, Joan
    Sullivan, Beth
    Di Santo, Nicola
    Elmeliegy, Mohamed
    Lin, Xun
    Quek, Ruben G. W.
    Czibere, Akos
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC)
    Agarwal, Neeraj
    Shore, Neal D.
    Dunshee, Curtis
    Karsh, Lawrence Ivan
    Azad, Arun
    Fay, Andre P.
    Carles, Joan
    Sullivan, Beth
    Di Santo, Nicola
    Elmeliegy, Mohamed
    Lin, Xun
    Quek, Ruben G. W.
    Czibere, Akos
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.
    Kessel, Adam
    McFarland, Taylor Ryan
    Sayegh, Nicolas
    Morton, Kathryn
    Sirohi, Deepika
    Kohli, Manish
    Swami, Umang
    Nussenzveig, Roberto
    Agarwal, Neeraj
    Maughan, Benjamin Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.
    Agarwal, Neeraj
    Azad, Arun
    Fay, Andre
    Carles, Joan
    Shore, Neal D.
    Nordquist, Luke T.
    Karsh, Lawrence Ivan
    Dunshee, Curtis
    Nandakumar, Srinand Ponnathapura
    Sullivan, Beth
    Czibere, Akos
    Wang, Fong
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) versus placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC).
    Agarwal, Neeraj
    Azad, Arun
    Carles, Joan
    Fay, Andre P.
    Matsubara, Nobuaki
    Heinrich, Daniel
    Szczylik, Cezary
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Voog, Eric
    Jones, Robert J.
    Shore, Neal D.
    Dunshee, Curtis
    Zschaebitz, Stefanie
    Lin, Xun
    Healy, Cynthia G.
    Di Santo, Nicola
    Zohren, Fabian
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
    Azad, Arun A.
    Fizazi, Karim
    Matsubara, Nobuaki
    Saad, Fred
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Shore, Neal D.
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Lin, Xun
    Deannuntis, Liza
    Di Santo, Nicola
    Zielinski, Michael A.
    Agarwal, Neeraj
    EUROPEAN JOURNAL OF CANCER, 2024, 213
  • [30] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
    Fizazi, Karim
    Tran, Namphuong
    Fein, Luis Enrique
    Matsubara, Nobuaki
    Antolin, Alfredo Rodriguez
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary Beth
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345